Glucagon-like peptide 1 (GLP-1)
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.283 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. SCOPE OF REVIEW: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. MAJOR CONCLUSIONS: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- Molecular Metabolism
- Topic
- Diabetes Treatment and Management
- Field
- Medicine
- Canadian institutions
- Lunenfeld-Tanenbaum Research InstituteUniversity of Toronto
- Funders
- European Research CouncilBERLIN-CHEMIECanadian Institutes of Health ResearchMerck Sharp and DohmeMedical Research CouncilJohnson and JohnsonServierNovo NordiskNational Institute for Health and Care ResearchNovo Nordisk FondenDeutsche ForschungsgemeinschaftZafgenIndiana UniversityBanting and Best Diabetes Centre, University of TorontoWellcome TrustAlexander von Humboldt-StiftungNovartis PharmaHelmholtz AssociationNovartisMerck KGaANational Institute of Diabetes and Digestive and Kidney DiseasesSanofiMerckPfizerAstraZenecaEli Lilly and CompanyBoehringer Ingelheim
- Keywords
- Glucagon-like peptide-1Glucagon-like peptide-2GlucagonProglucagonIncretinPeptideChemistryInternal medicineDiabetes mellitusEndocrinologyMedicineInsulinBiochemistryType 2 diabetes
- Has abstract in OpenAlex
- yes